Home > Healthcare > Medical Devices > Diagnostic Devices > Neurological Biomarkers Market

Neurological Biomarkers Market Share

Report ID: GMI12334
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Neurological Biomarkers Market Share

The competitive landscape in the market is characterized by a mix of global pharmaceutical and biotechnology companies and regional players. Established pharmaceutical giants offer well-known neurological biomarkers under various brand names. Companies are focusing on product differentiation, regulatory approvals, and strategic partnerships to strengthen their position in this competitive market.

Neurological Biomarkers Market Companies

Few of the prominent players operating in the neurological biomarkers industry include:

Abbott Laboratories
ACOBIOM
Alseres Pharmaceuticals
Banyan Biomarkers
Bio-Rad Laboratories
DiaGenic ASA
Johnson & Johnson Services
Merck KGaA
QIAGEN
Quanterix
Rules-Based Medicine
Thermo Fisher Scientific

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global neurological biomarkers industry was valued at USD 9.5 billion in 2024 and is estimated to grow at a 10.9% CAGR from 2025 to 2034, driven by the rising prevalence of neurodegenerative diseases.

The proteomic biomarker segment was valued at USD 3.1 billion in 2024, bolstered by innovations in proteomics that enhance the detection and quantification of biomarkers.

The U.S. neurological biomarkers market was valued at USD 3.7 billion in 2024, driven by the increasing prevalence of disorders such as Alzheimer's and Parkinson's.

Key players in the industry include Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals, Banyan Biomarkers, Bio-Rad Laboratories, DiaGenic ASA, Johnson & Johnson Services, Merck KGaA, QIAGEN, and Quanterix.